Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.61
  • Today's Change-0.045 / -0.97%
  • Shares traded918.00
  • 1 Year change-6.40%
  • Beta1.0457
Data delayed at least 15 minutes, as of Feb 13 2026 20:45 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

  • Revenue in USD (TTM)0.00
  • Net income in USD-78.49m
  • Incorporated2004
  • Employees153.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sagimet Biosciences Inc0.00-57.67m164.56m14.00--1.38-----1.79-1.790.003.670.00----0.00-38.04-40.69-39.78-43.01-------6,987.70----0.00---100.00---63.46------
MDxHealth SA103.07m-31.43m168.29m312.00------1.63-0.7275-0.72752.21-0.16690.66147.006.20330,349.30-20.17-40.27-29.24-50.7564.4857.38-30.50-76.841.02-0.81121.10--28.2950.1911.67--96.87--
Tharimmune Inc0.00-10.32m169.03m2.00--5.25-----4.11-4.110.000.8540.00----0.00-159.36-169.40-225.01-410.04------------0.0255-------30.89------
Cartesian Therapeutics Inc1.93m-50.61m169.54m66.00------87.98-1.97-1.970.0743-1.380.0047--0.694329,196.97-11.59-33.50-12.10-45.25-----2,489.83-128.46--------49.6442.2769.90--186.63--
Editas Medicine Inc46.38m-199.84m171.81m246.00--12.20--3.70-2.38-2.380.54540.14430.1753--11.24188,548.80-75.51-34.19-101.13-38.43-----430.84-373.02----0.8145---58.649.50-54.74--7.43--
Zentalis Pharmaceuticals Inc26.87m-149.32m172.68m166.00--0.6828--6.43-2.08-2.080.37433.500.0691----161,837.30-38.39-43.59-43.54-49.56-----555.80-1,402.74----0.00------43.24---8.89--
Tiziana Life Sciences Ltd - ADR0.00-12.84m174.99m8.00--17.95-----0.1136-0.11360.000.07740.00----0.00-93.18-57.21-231.54-73.22------------0.0115------32.94--37.77--
Galectin Therapeutics Inc0.00-37.44m177.94m15.00---------0.5913-0.59130.00-1.920.00----0.00-178.33-117.54---197.34-----------3.57---------5.35------
Molecular Partners AG (ADR)0.00-78.49m179.03m153.00--1.38-----2.13-2.130.003.330.00----0.00-45.23-13.09-49.34-15.66--99.25---56.51----0.0158---29.38-24.5912.81---17.26--
C4 Therapeutics Inc30.11m-119.08m183.17m110.00--0.9079--6.08-1.67-1.670.42252.080.0939--3.57273,709.10-37.12-26.50-42.35-29.90-----395.51-310.19----0.00--71.4410.7220.51---33.16--
SAB Biotherapeutics Inc114.70k-21.37m183.29m63.00--1.118.341,597.96-2.81-2.810.00433.480.001--0.34921,820.6415.80--17.22------16,338.04------0.0197---40.94--19.17------
Insight Molecular Diagnostics Inc4.40m-60.78m184.65m46.00------41.95-2.83-2.830.1643-0.32130.07715.6718.8595,695.65-106.49-41.57-124.80-46.8654.7324.70-1,380.69-2,290.772.73-171.82----25.15---136.17---10.88--
Ovid Therapeutics Inc6.61m-36.33m184.86m23.00--2.26--27.97-0.5112-0.51120.0930.62820.0794----287,391.30-43.64-13.89-49.07-15.44-----549.62-40.79----0.00--44.50--49.50---7.98--
Sol Gel Technologies Ltd18.97m-8.99m187.20m34.00--7.19--9.87-3.23-3.236.819.340.4891--2.25557,941.20-23.17-29.32-27.70-33.19-----47.37-138.22----0.00--642.47-12.8161.16---68.01--
Voyager Therapeutics Inc31.32m-126.78m188.48m172.00--0.8556--6.02-2.17-2.170.53583.960.0877--2.64182,069.80-35.50-1.01-39.95-1.27-----404.85-2.34----0.00---68.00-5.18-149.12---14.53--
Data as of Feb 13 2026. Currency figures normalised to Molecular Partners AG's reporting currency: US Dollar USD

Institutional shareholders

8.89%Per cent of shares held by top holders
HolderShares% Held
Suvretta Capital Management LLCas of 30 Sep 20252.22m5.50%
BVF Partners LPas of 30 Sep 20251.35m3.35%
SmartHarvest Portfolios LLCas of 31 Dec 202512.31k0.03%
Morgan Stanley & Co. LLCas of 31 Dec 2025367.000.00%
UBS Securities LLCas of 31 Dec 2025349.000.00%
Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 30 Sep 2025157.000.00%
EverSource Wealth Advisors LLCas of 31 Dec 202524.000.00%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.